Welcome to our dedicated page for Legence news (Ticker: LGN), a resource for investors and traders seeking the latest updates and insights on Legence stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Legence's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Legence's position in the market.
Legence (Nasdaq: LGN) priced an upsized secondary underwritten offering of 8,402,178 Class A shares by selling stockholders affiliated with Blackstone at $45.00 per share, with underwriters granted a 30‑day option to buy up to an additional 1,260,326 shares on the same terms. The offering is expected to close on or about December 16, 2025, subject to customary closing conditions.
Legence is not selling shares in the offering and will receive no proceeds from the sale. A Form S-1 registration statement has been filed and declared effective by the SEC; Goldman Sachs and Jefferies are joint lead book‑running managers.
Legence (Nasdaq: LGN) announced that selling stockholders affiliated with Blackstone intend to offer 7,000,000 shares of Class A common stock in a secondary underwritten public offering on December 9, 2025.
The underwriters have a 30-day option to purchase up to an additional 1,050,000 shares. Legence is not selling shares and will not receive proceeds; the company will pay offering costs except underwriting discounts and commissions. Goldman Sachs and Jefferies are joint lead book-runners; Blackstone Capital Markets is co-manager. The offering is being made under a Form S-1 filed with the SEC and is not yet effective.
Legence (Nasdaq: LGN) announced the acquisition of Innovative Mechanical & Design (IMD) on December 2, 2025, with Eight Quarter Advisors serving as sell-side advisor.
IMD, based in Northern Colorado, reported a 70% CAGR over the last four years and serves healthcare, pharmaceutical, higher education, semiconductor, and hyperscaler customers. The deal is described as expanding Legence's installation, service, maintenance, and fabrication capabilities and deepening relationships with Fortune 100 and Nasdaq-100 clients. Legence is backed by Blackstone and positions IMD to scale nationally while retaining its existing operations and client focus.
Legence (Nasdaq: LGN) reported record quarterly revenues of $708.0 million for Q3 2025, up 26.2% year-over-year, and non-GAAP Adjusted EBITDA of $88.8 million, up 38.9% year-over-year. Total backlog and awarded contracts reached $3.07 billion, a 29.4% increase, with a consolidated book-to-bill of 1.5x. The company used IPO net proceeds of $780.2 million to pay down term debt, reducing net debt to approximately $650 million and net leverage to 2.4x. Legence completed two tuck-in acquisitions (AZPE and IMD) and signed a definitive agreement to acquire Bowers for $475 million. Q4 2025 revenue guidance is $600M–$630M; full-year 2026 guidance is $2.65B–$2.85B revenue and $295M–$315M Adjusted EBITDA.
Legence (Nasdaq: LGN) agreed to acquire The Bowers Group for approximately $475 million, combining cash $325M, stock ~$100M, and $50M deferred consideration. The deal expands Legence’s mechanical capabilities in the Northern Virginia/DC metro market and adds > 370,000 sq ft of fabrication capacity and ~1,700 employees. Bowers reported ~$767M revenue, $72M EBITDA and $69M net income for the twelve months ended Sept 30, 2025, with backlog and awards of ~$1.3B. Legence expects Bowers to generate $825M–$875M revenue and $75M–$85M non‑GAAP EBITDA in 2026. Transaction funding includes cash on hand, revolver borrowings and an anticipated $150M term‑loan upsize; pro forma net leverage ~2.9x. Closing expected Q1 2026, subject to customary conditions and regulatory approval.
Legence (Nasdaq: LGN) will release third quarter results for the period ended September 30, 2025 on Friday, November 14, 2025, before the market opens. The company will host an earnings conference call and live webcast on November 14, 2025 at 10:00 am ET to review results and operations.
The call is listen-only and will be broadcast via the company’s investor website at https://investors.wearelegence.com/. A replay of the webcast and the slide presentation will be available on the same site shortly after the call and remain accessible through December 14, 2025.
Legence (Nasdaq: LGN) amended its credit facilities on October 30, 2025, improving liquidity and extending maturities.
The $798 million Term Loan maturity was extended three years to December 16, 2031 and repriced to SOFR + 2.25%, a 25 basis point reduction. The company also amended its Revolving Credit Facility, increasing the commitment to $200 million from $90 million, extending maturity to September 22, 2030, and setting the revolver rate to SOFR + 2.25%.
The company said proceeds from its recent IPO were used to repay debt and that the amendments, together with strong cash flow, enhance financial flexibility to support growth and strategic priorities.
Legence (NASDAQ:LGN) has successfully completed its Initial Public Offering (IPO), selling 26,000,000 shares of Class A common stock at $28.00 per share. The underwriters also partially exercised their option to purchase an additional 3,487,627 shares.
The company began trading on the Nasdaq Global Select Market on September 12, 2025, raising net proceeds of approximately $780.2 million after deducting underwriting discounts and commissions. The funds will be used to repay a portion of outstanding term loan borrowings and for general corporate purposes.
The IPO was led by Goldman Sachs and Jefferies as joint lead book-running managers, with several other prominent financial institutions serving as bookrunners and co-managers.
Legence (NASDAQ:LGN) has announced the pricing of its initial public offering, offering 26 million shares of Class A common stock at $28.00 per share. The company expects to raise approximately $688 million in net proceeds after deducting underwriting discounts and commissions.
Trading is set to commence on September 12, 2025, on the Nasdaq Global Select Market under the ticker symbol "LGN". The underwriters have a 30-day option to purchase up to 3.9 million additional shares. The proceeds will be used to repay a portion of outstanding term loan borrowings and for general corporate purposes.
Goldman Sachs and Jefferies are serving as joint lead book-running managers for the offering, which is expected to close on September 15, 2025.
FAQ
What is the current stock price of Legence (LGN)?
What is the market cap of Legence (LGN)?
